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Context: Polycystic ovary syndrome (PCOS) is themost common cause of anovulatory infertility and
may be associated with adverse pregnancy and neonatal outcomes. However, it is difficult to
establish how much of this risk is due to PCOS and how much to obesity.
Objective: This study aimed to determine the effect of PCOS upon fertility, pregnancy, and neo-
natal outcomes.
Design and Setting: Data were extracted from the Clinical Practice Research Datalink (CPRD), a
longitudinal anonymized primary care research database in the United Kingdom. Patients with a
diagnosis of PCOSwerematched to controls (1:2) by age (1 y), bodymass index ( 3U), and CPRD
practice. Standardized fertility ratiosbeforeandafterdiagnosis (indexdate)were calculated.Rates
of miscarriage, pre-eclampsia, gestational diabetes, premature delivery, delivery method, and
neonatal outcomes were compared.
Results: Nine thousand sixty-eight women with PCOS matched study criteria. Prior to index date
the standardized fertility ratio for patients with PCOS was 0.80 (95% confidence interval, 0.77–
0.83); following indexdate itwas1.16 (1.12–1.20). Theadjustedodds ratios (95%CI) formiscarriage
(1.70; 1.56–1.84), pre-eclampsia (1.32; 1.16–1.49), gestational diabetes (1.41; 1.2–1.66), and pre-
mature delivery (1.25; 1.1–1.43) were all increased compared with controls. Of PCOS births, 27.7%
were by Caesarean section compared with 23.7% of controls (1.13; 1.05–1.21). Infants born to
mothers with PCOS had an increased risk of neonatal jaundice (1.20; 1.03–1.39) and respiratory
complications (1.20; 1.06–1.37).
Conclusions: PCOS is associated with subfertility but fertility rates are restored to those of the
background population following diagnosis. Pregnancy complications and adverse neonatal out-
comesaremoreprevalent forwomenwithPCOS independentlyofobesity. (JClinEndocrinolMetab
101: 1664–1672, 2016)
Polycystic ovary syndrome (PCOS) is themost commonendocrine condition in women of reproductive age,
affecting 5–10% of the premenopausal population (1, 2).
The disorder is characterized by hyperandrogenism, insu-
lin resistance, and glucose intolerance, which lead to an
increased risk of type 2 diabetes (3). PCOS is also a com-
mon cause of anovulatory infertility (4, 5), such thatmany
women require assisted reproductive techniques to help
them conceive. Most commonly, this involves the use of
clomiphene citrate as an agent to induce ovulation. How-
ever, two randomized, double blind, placebo-controlled
trials have also established that metformin may improve
ovulation and conception rates in clomiphene-resistant
women with PCOS (6, 7). Previous studies have shown
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
Copyright © 2016 by the Endocrine Society
Received June 25, 2015. Accepted February 2, 2016.
First Published Online February 9, 2016
Abbreviations: BMI, body mass index; CI, confidence interval; CPRD, Clinical Practice Re-
search Datalink; GDM, gestational diabetes; HES, Hospital Episode Statistics; ICD, 10th
revision of the International Statistical Classification of Diseases and Related Health Prob-
lems; OR, odds ratio; PCOS, polycystic ovary syndrome.
O R I G I N A L A R T I C L E
1664 press.endocrine.org/journal/jcem J Clin Endocrinol Metab, April 2016, 101(4):1664–1672 doi: 10.1210/jc.2015-2682
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 13 June 2016. at 07:03 For personal use only. No other uses without permission. . All rights reserved.
that thereproductiveeffectsof thesyndromemayalsoextend
to a higher risk of many adverse outcomes in pregnancy, of
which gestational diabetes (GDM), gestational hyperten-
sion, premature birth, and early pregnancy loss are themost
studied (4, 5, 8, 9). Infants born tomothers with PCOSmay
also be at risk of adverse perinatal outcomes, includingmac-
rosomia, low Apgar score, and meconium aspiration (9).
However, estimates of risk for these complications are dif-
ficult to ascertain due to heterogeneity in study design, small
sample sizes, and inadequate matching for potential con-
founders such as obesity. In light of these uncertainties, we
sought to describe the fertility outcomes and establish the
relative risk of adverse pregnancy and neonatal outcomes in
a large contemporary cohort of patients with PCOS in the
United Kingdom.
Materials and Methods
The study used a retrospective cohort design using data from the
Clinical Practice Research Database (CPRD), a longitudinal,
anonymized research database derived frommore than 700 pri-
mary-care practices in the United Kingdom (10). Diagnostic in-
formation in CPRD is recorded using the Read code classifica-
tion, a United Kingdom general practice standard. In addition,
approximately 60%of thosepractices are linked tootherEnglish
data sources including the Hospital Episode Statistics (HES) da-
taset. This provides data on all inpatient and outpatient contacts
occurring within National Health Trusts.
Patient selection and matching of controls
Womenage 15–44 yearswith a diagnosis of PCOSdefined by
the Read code classification (Supplemental Table 1) or 10th re-
vision of the International Statistical Classification of Diseases
and Related Health Problems (ICD-10) classification (E28.2)
between 2000 and 2012 were selected and defined as cases. The
earliest diagnosis datewas selected as the indexdate.Aminimum
“wash-in” period of 12 months from the patient’s practice reg-
istration date to index date was used to maximize the likelihood
that the case represented an incident case. Patientswere followed
until either leaving theirpracticeoruntil the lastCPRDcollection
data for their practice. Female controls were matched at a ratio
of 2:1 by age (1 y), body mass index (BMI) ( 3 U), and same
primary care practice. All controls had to have remained at the
same practice for at least the same duration from index date as
their respective case, and followupwas limited in both groups to
that of the case.
Outcomes and analysis
Baseline characteristics for cases and controls were presented
and compared using univariate statistics (t test for continuous
variables and 2 for categorical variables).
Infertility was defined by relevant Read code (Supplemental
Table 2) recorded for consultations within the primary care da-
taset. To assess the relationship between PCOS and infertility,
time between first diagnosis of PCOS and first consultation for
infertility was described graphically and by summary statistics.
Fertility was compared between the two cohorts using standard-
ized fertility ratios based on 10-year age bands using the non-
PCOS population as the reference.
Miscarriages resulting in hospital admission were identified
through secondary care sources. Crude relative risk of miscar-
riage was calculated. Multivariate logistic regression predicting
miscarriage vs delivery was also performed adjusting for age,
BMI, number of previous births, and smoking history.
Complications of pregnancywere defined as premature birth,
GDM, and pre-eclampsia, and were ascertained from both the
primary and HES data sources (Supplemental Table 3). Com-
plications were assigned to each delivery if theywere recorded in
the preceding 295 days. The relative risks of each complication
in the period, both before and after diagnosis of PCOS, were
calculated. In addition, the odds ratio (OR)was calculated using
multivariate logistic regression adjusting for age, BMI, multiple
gestation, number of previous births, and smoking history.
To consider the effect of metformin treatment on pregnancy
outcomes, date of conceptionwas estimated as 280 days prior to
delivery date for those pregnancies resulting in live birth. For the
miscarriage outcome, it was assumed that conception occurred
84 days prior to the event.Metformin usewas assumed based on
prescription at two defined time points: 1) 90 days prior to es-
timated conception date and, 2) within the estimated first tri-
mester of the pregnancy.
Hospital births were identified from the HES dataset. Deliv-
erymethodwas defined by procedural codes (OPCS-4) and clas-
sified as normal vaginal delivery, elective caesarean, emergency
caesarean, forceps delivery, and vacuum delivery (Supplemental
Table 4). Method of delivery and birth outcome was described
and compared between cohorts using the 2 test. In addition,
multivariate logistic regression was used to examine the associ-
ation of PCOS status with caesarean compared with vaginal de-
livery and the likelihood of twin delivery. Additional covariates
included in the model were age, BMI, GDM, history of pre-
eclampsia, and number of previous births. Length of stay, ag-
gregated by delivery method, was compared using the t test.
Using the family numberwithinCPRD, it was possible to link
females with their children for a proportion of subjects. This
allowed fordiagnoses relating toneonatal admissions (definedas
those occurring between birth and 7 d) to be compared. We
selected the sixmost commongroupsof related complicationson
the neonate’s inpatient record: jaundice (ICD-10 P580–P599),
respiratory (P200-P229, P285, P288, and P289), feeding issues
(P920–P929), overweight (P080, P081), low birth weight
(P050–P059, P070–P072), and hypoglycemia (P703, P704).
Analyseswere adjusted for age, BMI,multiple gestation, number
of previous births, and smoking history.
Studies using the CPRD are covered by ethics approval
granted by Trent Multicenter Research Ethics Committee (Ref-
erence 05/MRE04/87). CPRD Independent Scientific Advisory
Committee approval was granted for this study (ISAC 13–192).
Results
Figure 1 shows the identification of PCOS patients, of
whom9068 could bematched to two non-PCOS controls.
The baseline characteristics of these patients are shown in
Table 1. There were significant differences between the
PCOS and control cohorts for the number of primary care
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contacts (9.0 vs 7.6, respectively) in the previous year. There
was considerable missing data for ethnicity, although this
was lower for patients with PCOS compared with controls
(33.0vs36.9%).Therewasa largerproportionofpatientsof
Indian, Pakistani, orOtherAsianorigin comparedwith con-
trols. Patients with PCOS were less likely to have ever
smoked tobacco products (56.9 vs 52.9%).
Infertility consultations
Of women identified with PCOS, 1529 (16.9%) had
previously consulted their primary care practice regarding
issues of infertility comparedwith 800 (4.4%) of controls;
a crude rate ratio of 4.69 (95% confidence interval [CI],
4.30–5.11). Respective figures following PCOS index
date were 796 (8.8%) vs 496 (2.7%); a crude rate ratio of
3.59 (3.21–4.02). Figure 2 (upper panel) shows time from
index date to first consultation for infertility. Four-hun-
dred twenty-three (18.2%)womenwith PCOS consulting
their primary care practice for issues relating to infertility
did so within  90 days of first PCOS diagnosis.
Of patients with PCOS, 413 (4.6%) had a history of
assisted reproduction compared with 188 (1.0%) of con-
trols. Following index date, 507 (5.6%) of cases had a
record associated with assisted reproduction compared
with 110 (0.6%) of controls. Subsequent to assisted re-
production, 286 (56.4%) of cases and 41 (37.3%) of con-
trols had conceptions resulting in either hospital birth or
miscarriage.Details of the fertility treatmentsprovidedare
given in Supplemental Table 5.
Age-specific fertility rates
During the study period (before and after index date)
the overall fertility rate for women with PCOS was 67.3
per 1000 years comparedwith 70.6 for thosewithout. The
respective fertility rates pre- and postindex dates were
57.5 vs 71.8 and 79.8 vs 68.7. The age standardized ratios
were 0.80 (95% CI, 0.77–0.83) prior to index date and
1.16 (95% CI, 1.12–1.20) after. Figure 2 (lower panel)
shows the age-specific fertility rates byPCOS status before
and after the index date.
Pregnancy risks
There were 6861 pregnancies resulting in hospital ad-
mission formiscarriage or delivery for womenwith PCOS
and 15 214 for those without (Table 2). Risk of miscar-
riage was increased for women with PCOS; the overall
crude risk was 1.56 (95% CI, 1.45–1.68): 1.77 (1.61–
1.95) before diagnosis and 1.35 (1.21–1.51) after. After
adjusting for age, BMI, smoking status, and prior births,
the OR was 1.70 (1.56–1.84). The respective ORs before
and after index date were 1.99 (1.79–2.24) and 1.47
(1.29–1.67) (Figure 3).
During those pregnancies resulting in live birth, the
overall crude risk of pre-eclampsia was 1.31 (1.16–1.46).
In the adjusted analyses, the OR was 1.31 (1.16–1.49);
1.23 (1.03–1.46) prior to diagnosis and 1.40 (1.17–1.68)
afterward.Theoverall crude riskofGDMwas1.43 (1.23–
1.67). In the adjusted analyses the OR was 1.42 (1.21–
1.67); 1.21 (0.94–1.54)prior todiagnosis and1.61 (1.29–
2.01) afterward. Prematuredeliverywas also increased for
womenwithPCOS.Theoverall crude riskwas1.27 (1.13–
1.44). After adjusting for other factors, the OR was 1.24
(1.09–1.41); 1.24 (1.03–1.49) prior to diagnosis and 1.26
(1.05–1.52) afterward (Figure 3). In a sensitivity analysis
restricted to singleton births there was little difference in
the adjusted ORs compared with the main analysis (Sup-
plemental Table 6). In a further sensitivity analysis re-
stricted to the 4355 patients with a diagnosis of either
PCOS or Stein-Leventhal syndrome and their respective
controls, slightly higher adjusted ORs were observed for
all outcomes (Supplemental Figure 1).
Effect of metformin
For the analysis restricted to PCOS patients treated
with metformin relative to other nonmetformin treated
patients, there was a significant increase in pre-eclampsia
associatedwithmetformin use in both the 90 days prior to
estimated conception (OR, 1.54; 95%CI, 1.06–2.23) and
the first trimester of pregnancy (OR, 1.54; 95%CI, 1.07–
2.22) but no significant difference in any other pregnancy
related outcomes (Supplemental Figure 2).
Figure 1. Patient selection.
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Delivery methods
Supplemental Table 7 shows themethod of delivery for
women with and without PCOS. Of PCOS births, 1606
(27.7%) were by caesarean section compared with 3243
(23.7%) of non-PCOS. In logistic regression, the OR of
caesarean delivery for PCOS was 1.13 (1.05–1.21) after
adjustment for other covariates including pre-eclampsia
(2.54; 2.14–3.00) and GDM (2.63; 2.25–3.06). Mean
length of stay for delivery was significantly greater for
women with PCOS (3.8 vs 3.5 d; P .002; Supplemental
Table 7). After adjustment for age, BMI, GDM, pre-ec-
lampsia, and premature delivery, the respective means
were 3.7 vs 3.5 days (P  .001).
Neonatal outcomes
Delivery outcome was available for 5757 (99.3%)
PCOS births and 13 607 (99.3%) non-PCOS births (Sup-
plemental Table 8). Multiple births occurred in 146
(2.5%) of PCOS births and 226 (1.7%) of non-PCOS
births, an increased relative rate for mothers with PCOS
(OR, 1.54; 95% CI, 1.22–1.95).
Apgar scores (11)were available for1731 (30.1%)chil-
dren born to mothers with PCOS and 4217 (31.0%) born
to mothers without PCOS. Respective Apgar scores were
6.33 and 6.43 at 1minute and 6.97 and 7.02 at 5minutes,
and were not significantly different between groups.
Neonatal inpatient admissions records for children
could be linked to 3634 (62.7%) of births forwomenwith
PCOS and 8557 (62.4%) of those without. Table 3 shows
thenumberofdefinedneonatal complications recordedon
these admissions. There were significant increases for
jaundice (1.20; 1.03–1.39) and respiratory complications
(1.20; 1.06–1.37).
Discussion
In this large population-based study, a diagnosis of PCOS
was associated with a lower fertility rate, increased risk of
Table 1. Baseline Characteristics for Patients With PCOS and Controls
Baseline Characteristic
Study Arm
PPCOS Non-PCOS
No. of patients 9068 18 136
Followup (y), mean, SD 4.2 3.3 4.2 3.3 1.000
Observation period pre-index (y), mean, SD 5.3 3.7 6.5 3.8 .001
Age (y), mean, SD 27.3 6.4 27.3 6.4 .808
Ethnicity
Bangladeshi, n, % 27 0.3 60 0.3 .001
Black (African/Caribbean/Other), n, % 174 1.9 331 1.8
Chinese, n, % 13 0.1 22 0.1
Indian, n, % 173 1.9 173 1.0
Mixed, n, % 52 0.6 100 0.6
Other Asian, n, % 77 0.8 83 0.5
Other, n, % 103 1.1 202 1.1
Pakistani, n, % 143 1.6 160 0.9
Unknown/not recorded, n, % 2990 33.0 6701 36.9
White, n, % 5316 58.6 10 304 56.8
Primary care contacts in previous year 9.0 7.8 7.6 7.0 .001
Prescribed oral contraception  90 d of index date, n, % 2712 29.9 6508 35.9 .001
History of assisted reproduction, n, % 413 4.6 188 1.0 .001
BMI (kg/m2), mean, SD 27.7 6.4 27.5 6.3 .019
Underweight ( 18 kg/m2), n, % 187 2.1 283 1.6 .001
Normal (18–25 kg/m2), n, % 3543 39.1 7581 41.8
Overweight ( 25–30 kg/m2), n, % 2330 25.7 4543 25.0
Obese ( 30–40 kg/m2), n, % 2637 29.1 5013 27.6
Extremely obese ( 40 kg/m2), n, % 371 4.1 716 3.9
BP
No. with BP recorded, n, % 5378 59.3 15 529 85.6
Systolic BP (mm Hg), mean, SD 118.7 13.5 118.3 13.0 .046
Diastolic BP (mm Hg), mean, SD 74.8 9.7 73.5 9.6 .001
Hypertensive, n, % 362 6.7 879 5.7 .001
Smoking status .001
Never smoked, n, % 5159 56.9 9590 52.9
Ex-smoker, n, % 1511 16.7 3439 19.0
Current smoker, n, % 2364 26.1 5065 27.9
Not recorded, n, % 34 0.4 42 0.2
Abbreviation: BP, blood pressure.
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adverse pregnancy and neonatal outcomes, and of oper-
ative delivery, which were not attributable to obesity.
We observed an approximate 4-fold increase in con-
sultations for infertility in women with PCOS compared
with matched controls. This is reflected in lower fertility
rates for women with PCOS prior to diagnosis, particu-
larly in younger patients. This may reflect a more severe
phenotype presenting at this age, but is also consistent
with a trend toward regularization of the menstrual cycle
in women with PCOS with advancing age (12). After di-
agnosis, fertility rates were restored in all age groups to
those of the background population, suggesting that in-
fertility inwomenwithPCOS is eminently treatable.How-
ever, it is not possible from the data to compare the in-
Figure 2. Upper panel: Time from index date (first diagnosis of PCOS) to consultation for infertility. Left upper panel: PCOS cases. Right upper
panel: Non-PCOS cases. Lower panel: Standardized specific fertility rates for women with and without PCOS, before and after index date.
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tention to conceive between females with and without
PCOS.
We also confirmed an increased risk of miscarriage in
womenwith PCOS.Only a few studies have examined the
association between PCOS and early pregnancy loss (13–
17). Some of these suggested that the risk of spontaneous
abortion was higher in women with PCOS but only one
study adjusted for obesity and fertility treatment (13)
which are themselves known to be associated with an in-
creased risk (18). In our study,whichmatched patients for
BMI, PCOS was associated with a significant increase in
pregnancy loss both before and after PCOS diagnosis.
For those pregnancies resulting in live birth there was
also significant increases in pre-eclampsia,GDM,andpre-
mature delivery. Previous studies have suggested that the
risk of GDM is increased in women with PCOS, but in-
terpretation of these studies and estimates of risk are dif-
ficult because of differences in studydesign and small sam-
ple sizes.Onepopulation-based study estimated a2.4-fold
increased risk of GDM in women with PCOS compared
with women without a diagnosis of PCOS or symptoms
(19). However, the PCOS group was significantly older
and had a higher prevalence of multiple gestation than
controls, which themselves are risk factors for GDM. Fur-
thermore, given that groupswere notmatched for obesity,
it is unclear howmuch of these riskswere due to PCOSper
se and how much to obesity, which is common in this
patient population and is itself associated with a higher
risk of GDM. Indeed, one previous study showed that the
prevalence of GDM did not differ among women with
PCOS and controls when weight was matched for (20). In
contrast, Roos et al (9), in a large population-based study
of singleton births in Sweden, found that the risk of GDM
was more than doubled in women with PCOS, even after
adjustment for age, BMI, and use of assisted reproductive
technology. This resonates with our understanding of
PCOS as a metabolic disorder underpinned by defects in
insulin secretion and sensitivity. Our observations are
Figure 3. Adjusted† ORs for GDM, pre-eclampsia, premature birth, and miscarriage for women with and without PCOS. *Denominator is all
pregnancies, adjusted for age, body mass index, number of previous births, and smoking history.
Table 2. Hospital Admissions for Births, Miscarriages,
and Complications of Pregnancy for Women With and
Without PCOS
PCOS Non-PCOS
n % n %
Before index date
Identified pregnancies 3369 9437
Births 2778 82.5 8503 90.1
GDM 93 3.3 235 2.8
Pre-eclampsia 188 6.8 466 5.5
Premature 171 6.2 427 5.0
Miscarriage 591 17.5 934 9.9
After index date
Identified pregnancies 3492 5777
Births 3021 86.5 5200 90.0
GDM 160 5.3 183 3.5
Pre-eclampsia 236 7.8 302 5.8
Premature 214 7.1 288 5.5
Miscarriage 471 13.5 577 10.0
Combined
Identified pregnancies 6861 15 214
Births 5799 84.5 13 703 90.1
GDM 253 4.4 418 3.1
Pre-eclampsia 424 7.3 768 5.6
Premature 385 6.6 715 5.2
Miscarriage 1062 15.5 1511 9.9
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consistent with these findings, albeit that the OR was
slightly lower at 1.4. This is also in keeping with our pre-
viousCPRDstudy,which showed thatwomenwith PCOS
had a 50% increased risk of type 2 diabetes in the United
Kingdom population (3).
Our finding of an increased risk of pre-eclampsia is
consistent with many (4, 21), but not all (22) previous
studies but the mechanisms by which this develops are
unclear. One such pathway may involve hyperinsulin-
emia,which is a common finding even in leanpatientswith
PCOS, and which has been implicated in hypertension
developing in pregnancy (22, 23).
Two meta-analyses assessing pregnancy outcomes in
womenwith PCOShave suggested that the risk of preterm
delivery is increased in patients with the syndrome (4, 24).
Of the studies that informed these analyses (5, 20, 22, 25,
26), only one excluded patients with multiple gestation
(26),which is amajor risk factor for pretermdelivery in its
own right. Mikola et al (22) found that PCOS per se lost
its significance as a risk for preterm birth in a multivariate
analysis which identified multiple gestation and nullipar-
ity as independent predictors. Thismay be in keepingwith
the observation that many women with PCOS need ovu-
lation induction to conceive and that such treatment is
more likely to result inmultiple gestation pregnancies.We
found an increased risk of premature delivery in our pop-
ulation, which could not be explained by differences in
age, BMI, multiple gestation, or previous pregnancy. This
observation is in keepingwith that ofRoos et al (9) in their
study of singleton pregnancies. However, obesity may ex-
acerbate the risk of pretermbirth.De Frène and colleagues
(27) reported an almost seven-fold increase in the propor-
tion of preterm deliveries when comparing obese and
nonobese females with PCOS.
The effect ofmetformin use forwomenwith PCOSwas
inconclusive as this study was not powered to detect dif-
ferenceswithin the PCOS cohort and the effect ofmultiple
testing should be considered in interpreting these results.
However, therewas a significant increase in pre-eclampsia
for those women identified as being prescribedmetformin
prior to estimated conception and during their first tri-
mester. It is difficult to be certain whether this represents
a true adverse effect ofmetformin therapy or ismore likely
a reflection of residual confounding due to preferential
prescribing inhigher riskpregnancies.A large,multicenter
randomized clinical trial found no effect of metformin,
administered late in the first trimester through to delivery,
on pregnancy outcome, with the exception of an apparent
reduction in later miscarriage and preterm delivery (28).
We did not find an effect of metformin on early miscar-
riage rate, consistent with previous studies (29, 30).
In our studywe have also shown that caesarean section
wasmore commonas amethodof delivery in patientswith
PCOS, even after adjustment for possible confounders.
This is in agreement with some (9) but not all studies (4).
Indeed, in a meta-analysis of pregnancy outcomes in
women with PCOS where subgroup analysis was re-
stricted to higher validity studies, no increased risk was
observed (4). An increased rate of operative delivery was
associated with a 6% increased length of stay in fully ad-
justed analyses. This is likely to lead to adverse health
economic consequences, of a similarorderofmagnitudeas
that apparent in obesity (31). As anticipated, a diagnosis
of PCOS was also associated with an increased risk of
multiple births likely related to a greater use of assisted
conception, albeit that multiple births only accounted for
a small fraction of the total.
Neonatal outcomes were generally worse for infants
born to mothers with PCOS although we did not find a
difference in stillbirth nor in Apgar scores with controls.
This contrasts with Roos et al (9), who found an increased
risk of low Apgar score at 5 minutes in infants born to
mothers with PCOS but no increased risk of neonatal
death. However, we did note a significantly increased risk
for neonatal jaundice and respiratory distress. To our
knowledge, ours is the first study to report such associa-
tions. There was also a trend toward increased risk of low
birth weight in our study, a finding which has been shown
Table 3. Neonatal Complications Reported for Offspring of Women With PCOS and Matched Controls
Complication
PCOS
(n  3707)
Non-PCOS
(n  8656)
Adjusted ORa (95% CI) Pn % n %
Jaundice 326 8.8 588 6.5 1.20 (1.03–1.39) .016
Respiratory 420 11.3 785 8.7 1.20 (1.06–1.37) .005
High birth weight 40 1.1 104 1.2 0.97 (0.67–1.41) .894
Low birth weight 242 6.5 439 4.9 1.19 (1.00–1.42) .054
Hypoglycemia 124 3.3 218 2.4 1.31 (0.99–1.74) .062
Feeding issues 85 2.3 139 1.5 1.21 (0.96–1.52) .106
Abbreviation: OR, odds ratio.
a Adjusted for age, BMI, number of previous births, multiple gestation, and smoking history.
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in one (32) but not other previous studies (9, 20, 22, 33),
and also hypoglycemia.
Significant strengths of our study include the large sam-
ple size and careful adjustment for possible confounders,
but our study has certain limitations. In common with
other studies of this type, the CPRD collects data from
routine practice; thus, there are missing data and coding
imperfections. However, whereas these may introduce
noise into the study, they are unlikely to introduce bias.
We were dependent upon hospital data for the accurate
ascertainment of births and therefore births outside Na-
tional Health Service hospitals (private or home births)
could not be included. Home births represent approxi-
mately 2.5% of all births in the United Kingdom and it is
possible that there are differences in this proportion for
those with and without PCOS due the perceived risk of
complications. Similarly, we did not have access to data
for infertility consultations that occurred in the private
sector.Wewere unable to analyze the effect of PCOS phe-
notype on reproductive outcome given that these data are
not captured in routine primary care. Based on routine
data, we were also unable to determine the proportion of
women in each group who were seeking to become preg-
nant. Within the PCOS group, fewer women were pre-
scribed contraceptives within  90 days of index date. It
is also noticeable (Figure 2Ai) that forwomenwith PCOS,
first consultations for infertility are not uniformly distrib-
uted but centered around first diagnosis of PCOS. This
may be due to PCOS being diagnosed during investiga-
tions for infertility, which may be indicative that the pa-
tient is seeking to become pregnant.
In conclusion, we have shown that younger women
with PCOS have reduced fertility but that fertility rates
may be restored to those of the background population
after diagnosis. We have also confirmed an adverse effect
of PCOS, independently of obesity, on several pregnancy
outcomes, including GDM, pre-eclampsia, and preterm
birth. These observations suggest that women with PCOS
require more intensive monitoring during pregnancy, and
emphasize the need for additional studies to understand
the mechanisms by which these complications arise.
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